If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
75
results.
Updated on
19/04/2025 [07:25:00]
Results 25 to 50 of 75
Absstract of: US2025082751A1
The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.
Absstract of: WO2025054360A1
The disclosure provides for a vaccine depot formulation that comprises a biodegradable thermosensitive hydrogel that has been loaded or embedded with nanoparticles that comprise an antigen and adjuvant, and uses thereof for protecting a subject from an infection or disease.
Absstract of: US2025084490A1
The invention refers to a method for simultaneous detection and quantification of Listeria monocytogenes, Salmonella spp. and Shiga toxin-producing Escherichia coli (STEC), from any kind of sample related to food production, including complex food matrices such as fish, meat, or fruit; or simple matrices such as water, or food contact surfaces. The method of invention allows specific quantification of the above-mentioned pathogens simultaneously thanks to specificity of designed primers for the qPCR reaction. It is also highly reliable because the method includes a system to adequately control the quantification of pathogens within the matrix. This system comprises the inoculation of samples with a known concentration of a transformed microorganism (host) carrying a chimeric sequence, acting as an internal control host for the whole process.
Absstract of: AU2023312737A1
Provided herein are vaccine composition comprising a
Absstract of: US2025074952A1
Provided is a structure for capturing a compound that includes at least one gene or a product thereof, or a combination thereof among a group of genes involved in the intracellular and extracellular transport function of the compound, the gene or the product thereof being multi-componented.
Absstract of: KR20250031183A
본 발명은 표적단백질을 효율적으로 분비할 수 있는 살모넬라 균주 및 이의 제조방법에 관한 것으로, fliD 유전자가 불활성화되어, 플라젤린 단백질의 분비가 증가된 변이 살모넬라 균주를, 표적 단백질과 flgM 단백질의 융합단백질을 암호화하는 유전자를 포함하는 유전자 구조물로 형질전환하여, 표적 단백질과 flgM 단백질의 융합단백질 형태로 표적단백질을 분비하는 것을 특징으로 하는 살모넬라 균주 및 이의 제조방법에 관한 것이다.
Absstract of: US2025073163A1
The present invention provides a method of treating an infectious disease. The method comprises the step of administering to a subject in need thereof an effective amount of (i) a polymer-flavonoid conjugate, (ii) a flavonoid oligomer, or (iii) micelles having a shell formed by one or more polymer-flavonoid conjugates or one or more flavonoid oligomers, or the combination thereof, and having an agent encapsulated within the shell. The present method is effective to treat viral infection, e.g., severe acute respiratory syndrome coronavirus (SARS-CoV), enterovirus virus, HIV, hepatitis B virus, MERS-CoV, influenza virus, Dengue virus, respiratory syncytial virus, hepatitis C virus, monkeypox virus, human papillomavirus, methicillin-resistant Staphylococcus aureus, Pseudomonas, tuberculosis, Bacillus anthracis, Tetani bacterium, Streptococcus pneumoniae, meningococcus, Escherichia coli, Legionella, Neisseria gonorrhea, Neisseria meningitidis, and Salmonella.
Absstract of: US2025073282A1
The present invention relates to the technical field of probiotics, in particular to a Lactiplantibacillus plantarum GOLDGUT-LP618 having a function of resisting Salmonella infection and application thereof. The Lactiplantibacillus plantarum GOLDGUT-LP618 provided by the present invention is preserved in China General Microbiological Culture Collection Center, with the preservation number of CGMCC No. 28399. The strain has high resistance to acid and bile salt and can adapt to the digestive tract environment. The strain can inhibit Salmonella infection, relieve diarrhea, inflammation and intestinal damage caused by Salmonella infection, and promote intestinal health. The strain can be used for preparing functional foods, dietary supplements or drugs that can resist Salmonella infection and improve diarrhea and inflammation caused by Salmonella infection, and has good application prospects.
Absstract of: AU2023262222A1
The invention relates to a gelled reaction medium for the detection, identification, enumeration and/or isolation of at least one target microorganism in a sample that may contain same, comprising at least one binding partner specific to a component of a target microorganism or of a component derived from said microorganism, coupled to at least one nanoparticle to form at least one binding conjugate.
Absstract of: JP2023175686A
To provide compositions for use in enhancing human immune response and/or as adjuvants in vaccines.SOLUTION: A composition includes an antigen and a specific imidazopyrimidine compound.SELECTED DRAWING: None
Absstract of: KR20250030119A
본 발명은 신규한 살모넬라 엔테리티디스 온도감수성 변이주에 관한 것으로, 본 발명의 변이 균주는 야생형 균주가 번식하는 닭의 정상 체온인 40 내지 45 ℃에서 성장이 억제되어 집락 형성을 억제하므로, 면역화된 무리 내에서 백신 균주가 장기 순환함으로써 치명적인 복귀 돌연변이체가 될 수 있는 위험성이 없는 충분히 약화된 비병원성 백신 균주이며, 닭에서 살모넬라 엔테리티디스에 대항하여 충분한 안전성, 방어 효능 및 면역 반응을 나타냈고, 그에 일치한 표현형 및 유전형 변화도 보였으므로, 이를 온도감수성(온도민감성) 약독화 생균 백신의 유효성분으로 유용하게 사용할 수 있다.
Absstract of: JP2024012307A
To provide modified or mutant forms of secretin and compositions comprising the same, and methods for using modified or mutant forms of secretin and compositions for characterizing an analyte, e.g., a target polynucleotide.SOLUTION: The disclosure provides analyte detection using a modified secretin as a nanopore. The disclosure provides a modified secretin nanopore disposed in a membrane, wherein the modified secretin nanopore comprises a lumenal surface defining a lumen that extends through the membrane between a cis-opening and a trans-opening, wherein the lumenal surface comprises one or more amino acid modifications.SELECTED DRAWING: None
Absstract of: WO2025039454A1
A breast milk-derived Limosilactobacillus fermentum MSJK0025 capable of improving the intestinal flora condition and the use thereof. The breast milk-derived Limosilactobacillus fermentum MSJK0025 is deposited in the China General Microbiological Culture Collection Center with a deposit number of CGMCC No. 26426. The breast milk-derived Limosilactobacillus fermentum is a new strain isolated from breast milk of healthy puerperae, and is referred to as Limosilactobacillus fermentum MSJK0025. The strain has a good antibiotic sensitivity and stable inheritance of traits, has a good tolerance to acid, bile salts and artificial gastric/intestinal fluid, and has a fast growth rate and good safety. Furthermore, the strain has a strong intestinal colonization capability and can effectively inhibit intestinal pathogenic bacteria such as Escherichia coli, Staphylococcus aureus, Salmonella typhimurium and Candida albicans, but has no inhibitory effects on intestinal probiotics such as Lactobacillus and Bifidobacterium.
Absstract of: US2025064866A1
The present invention relates to the field of cancer therapy. In particular, the present invention relates to a first composition comprising a live attenuated bacterium for use in the treatment, prevention, reduction, inhibition, prevention of recurrence, or control of a neoplastic disease in a subject being or intended to be administered a second composition comprising a live attenuated bacterium, said bacterium being the same or different to that of the first composition and methods thereof.
Absstract of: WO2025042889A1
The present disclosure provides formulations, kits, and vaccines directed to immunization of animals against Salmonella. Methods of usng the formulations, kits, and vaccines for protection of avians against one or more species of Salmonella are also provided.
Absstract of: US2025064910A1
Technologies for the prevention and/or treatment of Salmonella infections.
Absstract of: US2025066429A1
The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.
Absstract of: EP4512482A2
The invention relates to an enriched population of modified lipopolysaccharide (LPS) molecular species being:- devoid of phosphate group at position C1 of the reducing end of their lipid A domain; and- substituted at position C6' of the non-reducing end of their lipid A domain by a hydrophilic moiety, with the proviso that said hydrophilic moiety is not a hydroxyl group.It also relates to compositions comprising the enriched population of modified LPS; and uses of naturally-occurring LPS molecular species and/or enriched population of modified LPS molecular species for treating and/or preventing cancer, inflammatory diseases or infectious diseases, and for stimulating an immune response or vaccinating a subject.
Absstract of: CN119491012A
本发明公开了一种重组鼠伤寒沙门氏菌的构建方法及其产品和应用，本发明中rSC0134(pS‑PlcC‑NetB)在免疫初期能够刺激机体产生充分的免疫应答，在免疫后期呈现出程序性的自我清除，具有一定安全性；rSC0134(pS‑PlcC‑NetB)免疫肉鸡后可产生强大的体液免疫，黏膜免疫和细胞免疫，保护肉鸡免受坏死性肠炎的感染；本发明构建了一种重组减毒鼠伤寒沙门氏菌疫苗载体平台，为开发针对鸡源传染病疫苗的递送平台提供了一种有前景的策略，具有较大的市场应用潜力和潜在的经济效益。
Absstract of: WO2025037284A2
A vaccine and methods of treatment thereof, wherein the vaccine comprises a recombinant Gram-negative bacteria genetically modified to express a first antigen fusion peptide comprising a neoantigen or series thereof, said neoantigen or series thereof associated with a first secretion signal from a double membrane-spanning secretion system and a second antigen fusion peptide comprising a homologous neoantigen or series thereof, associated with a second secretion signal from an outer membrane-spanning secretion system. The Gram-negative bacteria may be further modified for quadmodal transport. Specifically, the fusion peptides include signal peptides are each associated with a Type III (T3SS) and a Type V (T5SS) secretion system.
Absstract of: AU2025200704A1
Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella or by modification of the genes so that functional flagella are not produced, and/or are modified by deletion ofpagP or modification ofpagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin" and/orpagP'. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine and/or purine auxotrophs. The bacteria optionally are one or more of asct, purl'and msbB'. The immunostimulatory bacteria, such as Salmonella species, are modified to encode proteins that induce type I interferon (IFN) expression, or that are variants thereof that have increased activity to induce type I IFN expression, or that are variants thereof that result in constitutive expression of type I IFN. The bacteria can encode a modified Stimulator of Interferon Genes (STING) protein from a non-human species, that has lower NF-KB signaling activity, and, optionally, higher type I IFN pathway signaling activity, compared to human STING. The bacteria preferentially infect immune cells in the tumor microenvironment, or tumor-resident immune cells, and/or induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the
Absstract of: US2021077605A1
The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one further anti-cancer agent. The present invention further relates to a pharmaceutical composition comprising an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein, wherein the pharmaceutical composition further comprises at least one further attenuated strain of Salmonella comprising at least one copy of a further DNA molecule comprising a further expression cassette encoding a tumor antigen or a tumor stroma antigen.
Absstract of: CN119464322A
本发明公开了yncJ基因在调控鼠伤寒沙门氏菌毒力中的应用，属于生物技术领域。本发明通过构建鼠伤寒沙门氏菌的yncJ基因缺失菌株对yncJ基因的功能进行研究，发现将yncJ基因缺失后，菌株在巨噬细胞内的增殖能力显著降低；通过感染小鼠实验发现，yncJ基因缺失菌株对小鼠的致死能力显著降低。而且，yncJ基因缺失菌株的常规生化特性和体外生长速度未见明显变化，因此，yncJ基因缺失菌株具有生产防治鼠伤寒沙门氏菌的减毒疫苗的应用前景。
Absstract of: CN119432860A
本发明公开了一种检测肠炎沙门氏菌的试剂盒及其应用，属于生物分子检测技术领域。该试剂盒包括如下成分：核苷酸序列如SEQ ID NO.1所示的变构适配体探针、核苷酸序列如SEQ ID NO.3所示的模板链和核苷酸序列如SEQ ID NO.4所示的荧光报告探针。本发明试剂盒能将肠炎沙门氏菌同其他的杂质区分开，特异性强；可以得到可视化的荧光信号，易于判读；可以使模板链在反应中循环利用等温扩增产生Trigger链引导TtAgo蛋白高效、特异切割荧光报告探针，增大输出信号，且检测时间短，检测限低，灵敏度高，特异性好，具备实际推广应用前景。
Nº publicación: US2025051300A1 13/02/2025
Applicant:
HERGENROTHER PAUL J [US]
MUNOZ KRISTEN A [US]
THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS [US]
HERGENROTHER Paul J,
MU\u00D1OZ Kristen A,
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Absstract of: US2025051300A1
Small molecule inhibitors of the localization of lipoprotein CDE (LolCDE) complex that is found in the membrane of bacteria. Searches for suitable candidates for the LolCDE complex led to the discovery of an inhibitor named lolamycin. Lolamycin specifically targets Gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Salmonella typhimurium, and is selective over Gram-negative and Gram-positive commensal bacteria, thereby avoiding perturbation of the gut microbiome.
BOPI
Electronic site
